Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|03 Sep 2020||$0.0250||0.00%||Final||18 Sep 2020|
|04 Sep 2019||$0.0250||0.00%||Final||19 Sep 2019|
|21 Sep 2018||$0.0200||0.00%||Final||08 Oct 2018|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company that develops drugs for the treatment of a range of skin disorders. The company’s flagship product is Scenesse, a drug designed for the treatment of erythropoietic protoporphyria (EPP). EPP is a rare metabolic disorder which causes burns after brief exposure to visible light, especially sunlight. It is estimated that there are 5,000 to 10,000 EPP patients worldwide.
Clinuvel is also seeking to progress the use of Scenesse for the treatment of vitiligo, a skin disorder characterised by the appearance of white to off-white skin patches due to the loss of melanin production.
The company’s history dates back to 1987 when university researchers devised an idea of synthesising human hormones to protect the skin. Clinuvel shares have been listed on the ASX since 2001 and as a biopharmaceutical company, the Clinuvel share price can often be particularly volatile, bouncing around in response to announcements such as clinical trials and new launches.
|30 Jul 2021||$27.86||$-1.86||-6.26%||183,918||$29.19||$29.20||$27.77|
|29 Jul 2021||$29.72||$0.97||3.37%||92,810||$29.01||$29.93||$28.86|
|28 Jul 2021||$28.75||$0.16||0.56%||81,694||$28.59||$29.22||$28.23|
|27 Jul 2021||$28.59||$-0.71||-2.42%||63,733||$28.52||$29.19||$28.22|
|26 Jul 2021||$29.30||$-0.42||-1.41%||71,440||$29.75||$29.75||$28.95|
|23 Jul 2021||$29.72||$0.70||2.41%||85,313||$29.01||$29.93||$29.01|
|22 Jul 2021||$29.02||$0.54||1.90%||65,701||$28.79||$29.20||$28.71|
|21 Jul 2021||$28.48||$0.29||1.03%||68,764||$28.17||$28.98||$28.10|
|20 Jul 2021||$28.19||$0.29||1.04%||64,325||$27.90||$28.34||$27.11|
|19 Jul 2021||$27.90||$0.15||0.54%||47,599||$27.80||$28.04||$27.36|
|16 Jul 2021||$27.75||$-0.19||-0.68%||59,085||$27.80||$27.85||$27.50|
|15 Jul 2021||$27.94||$-0.42||-1.48%||64,164||$28.39||$28.44||$27.78|
|14 Jul 2021||$28.36||$0.70||2.53%||70,526||$27.89||$28.44||$27.53|
|13 Jul 2021||$27.66||$0.65||2.41%||91,733||$27.16||$28.10||$27.16|
|12 Jul 2021||$27.01||$-0.05||-0.18%||60,570||$27.30||$27.41||$26.81|
|09 Jul 2021||$27.06||$-0.61||-2.20%||103,786||$27.64||$27.67||$26.81|
|08 Jul 2021||$27.67||$-0.54||-1.91%||53,703||$28.25||$28.30||$27.54|
|07 Jul 2021||$28.21||$0.69||2.51%||120,291||$28.34||$28.40||$27.84|
|06 Jul 2021||$27.52||$-1.02||-3.57%||142,740||$28.35||$28.54||$27.33|
|05 Jul 2021||$28.54||$-1.57||-5.21%||78,778||$30.00||$30.00||$28.45|
|02 Jul 2021||$30.11||$-0.09||-0.30%||67,116||$30.00||$30.47||$29.86|
|01 Jul 2021||$30.20||$-0.50||-1.63%||98,521||$30.37||$30.80||$29.94|
|30 Jun 2021||Philippe Wolgen||Sell||122||$3,748,582||
|24 Jun 2021||Brenda Shanahan||Sell||25||$691,771||
|31 May 2021||Philippe Wolgen||Sell||102||$3,127,366||
|03 Mar 2021||Philippe Wolgen||Sell||104||$2,564,744||
|02 Mar 2021||Jeffrey Rosenfeld||Buy||670||$14,898||
|10 Sep 2020||Susan (Sue) Smith||Buy||420||$8,988||
|26 Aug 2020||Philippe Wolgen||Issued||1||$35,164,412||
Issue of securities. 1,513,750 - Performance Rights.
As per announcement on 01/09/2020.
|Ms Brenda Mary Shanahan||Non-Executive Director||Dec 2007||
Mrs Shanahan is a pioneer in the Australian finance community. The first female stockbroker, Mrs Shanahan has also spent more than two decades working and investing in medical R&D and commercialisation. She is currently a non-executive director of Phoslock Water Solutions Ltd. Mrs Shanahan is also a non-executive director of DMP Asset Management Ltd and SG Hiscock Ltd, a director of the Kimberly Foundation of Australia Ltd, and Chair of the Aikenhead Centre for Medical Discovery in Melbourne. Previously Mrs Shanahan was a member of the Australian Stock Exchange and an executive director of a stockbroking firm, a fund management company and an actuarial company. Until 2017, she was Chair of St Vincent's Medical Research Institute. Mrs Shanahan was formerly Chair of Challenger Listed Investments Ltd. Her experience across global markets and medical research provides value to the current Board and Group. She is Chair of the Audit and Risk Committee and member of the Nomination Committee
|Mrs Susan (Sue) Smith||Non-Executive Director||Sep 2019||
Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
|Dr Philippe J Wolgen||Chief Executive OfficerManaging Director||Dec 2005||
Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
|Mr Willem A Blijdorp||Non-Executive DirectorNon-Executive Chairman||Jan 2015||
Mr Blijdorp is an internationally recongnised entrepreneur who has helped build the B&S Group, one of the largest global trading houses, in a period spanning three decades. Willem now serves on its Supervisory Board and is a majority shareholder, focussing on the Group's development and expansion strategy. Mr Blijdorp was recognised for his expertise in merger and acquisitions and commercial leadership as the Ernst & Young Entrepreneur of the Year in the Netherlands, and runner-up in its European Union awards. He is a Chair member of Remuneration and Nomination committee. He is also member of the Audit and Risk Committee.
|Dr Karen Agersborg||Non-Executive Director||Jan 2018||
Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
|Dr Jeffrey Rosenfeld||Non-Executive Director||Nov 2019||
Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
|Mr Darren Keamy||Chief Finance OfficerCompany Secretary||Dec 2005||
|Darren Keamy||Chief Finance OfficerCompany Secretary||
|J P Morgan Nominees Australia Pty Limited||14,860,373||30.08%|
|HSBC Custody Nominees (Australia) Limited||9,877,178||19.99%|
|Acn 108 768 896 Pty Ltd||4,324,693||8.75%|
|Ender 1 Llc||2,590,824||5.24%|
|Citicorp Nominees Pty Limited||1,540,396||3.12%|
|Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retail Client)||1,002,756||2.03%|
|National Nominees Limited||636,062||1.29%|
|M Badcock And P Chu Superannuation Fund Pty Ltd||628,447||1.27%|
|Dr Mark Edwin Badcock||567,890||1.15%|
|Bnp Paribas Noms Pty Ltd (Drp)||557,672||1.13%|
|National Nominees Limited (Db A/C)||481,667||0.97%|
|Merrill Lynch (Australia) Nominees Pty Limited||323,059||0.65%|
|BNP Paribas Noms (NZ) Ltd (DRP)||261,411||0.53%|
|Mr David William Trevorrow||222,222||0.45%|
|Bnp Paribas Nominees Pty Ltd (Agency Lending Drp A/C||220,669||0.45%|
|Bnp Paribas Nominees Pty Ltd (Lgt Bank Ag Drp)||213,770||0.43%|
|Vulcancrest Pty Ltd (The Vulancrets A/C)||200,000||0.40%|
|Ms Nicoletta Muner||187,625||0.38%|
|Hsbc Custody Nominees (Australia) Limited AA/C 2||187,000||0.38%|
|Mr David John Lewis||183,165||0.37%|
Clinuvel Pharmaceuticals listed on the ASX in 2001 and only recently declared a profit for the first time in FY2017. Since then, the company went on to achieve increased profits across both FY2018 and FY2019. It also distributed final dividends of 2 cents and 2.5 cents per share for FY2018 and FY2019 respectively. As at 17 June 2020, Clinuvel has made no announcements regarding the status of its FY2020 dividend payment.
Having only started paying dividends over the last couple of years, Clinuvel Pharmaceuticals does not currently offer a dividend reinvestment plan.